The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort. by Benhamou, Mathilde et al.
The gap between practice and guidelines in the choice of
first-line disease modifying antirheumatic drug in early
rheumatoid arthritis: results from the ESPOIR cohort.
Mathilde Benhamou, Nathalie Rincheval, Carine Roy, Violaine Foltz, Sylvie
Rozenberg, Jean Sibilia, Thierry Schaeverbeke, Pierre Bourgeois, Philippe
Ravaud, Bruno Fautrel
To cite this version:
Mathilde Benhamou, Nathalie Rincheval, Carine Roy, Violaine Foltz, Sylvie Rozenberg, et
al.. The gap between practice and guidelines in the choice of first-line disease modifying an-
tirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort.. The Journal
of rheumatology, 2009, 36 (5), pp.934-42. <10.3899/jrheum.080762>. <inserm-00380632>
HAL Id: inserm-00380632
http://www.hal.inserm.fr/inserm-00380632
Submitted on 15 Mar 2010
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
J Rheumatol . Author manuscript
Page /1 15
The gap between practice and guidelines in the choice of first-line disease
modifying antirheumatic drug in early rheumatoid arthritis: results from
the ESPOIR cohort
Mathilde Benhamou 1 , Nathalie Rincheval 2 , Carine Roy 3 , Violaine Foltz 1 , Sylvie Rozenberg 1 , Jean Sibilia 4 , Thierry
Schaeverbeke 5 , Pierre Bourgeois 1 , Philippe Ravaud 3 , Bruno Fautrel 1 *
Service de Rhumatologie    1 AP-HP , H pital Piti -Salp tri re ô é ê è , Universit  Pierre et Marie Curie - Paris VI é , 47-83, boulevard de l H pital' ô
75651 PARIS Cedex 13,FR
Centre de coordination   2 CHRU Montpellier , H pital Lapeyronie ô , Montpellier,FR
D partement d pid miologie, biostatistique et recherche clinique   3 é 'é é AP-HP , H pital Bichat - Claude Bernard ô , 46 rue Henri Huchard 75018
Paris,FR
Physiopathologie et antibiologie microbiennes  4 Universit  Louis Pasteur - Strasbourg I : EA3432 é , FR
Service de rhumatologie  5 CHU Bordeaux , FR
* Correspondence should be adressed to: Bruno Fautrel <bruno.fautrel@psl.aphp.fr >
Abstract
Introduction
To compare rheumatologists  prescription for first disease-modifying anti-rheumatic drug (DMARD) in early rheumatoid arthritis’
(RA) in real-life settings with two clinical practice guidelines (CPG), STPR  and EULAR  and thus assess the gap between[1 ] [2 ]
practices and guidelines.
Methods
ESPOIR is a French multicentre cohort study that included 813 early arthritis patients between 2002 and 2005. Definite  and ‘ ’ ‘
probable  RA were defined according to ACR criteria and the level of diagnostic certainty. The objectives were to: 1/assess conformity’
between the observed first-line DMARD prescribed for those patients and the guidelines  recommended DMARD; and 2/conduct a’
mail survey of patients  usual rheumatologists to explore the reasons for their non-conformity with guidelines.’
Results
627 patients with definite or probable RA were identified. Conformity rates were 58  for STPR guidelines and 54  for EULAR% %
guidelines. At 6 months, 83 (34 ) patients with early RA did not receive any DMARD. Main determinants associated with conformity%
to guidelines were: disease activity and presence of severity predictive factors. The main reason leading to a discrepancy between
guidelines and daily practice appeared to be diagnostic uncertainty, i.e., the difficulty to reliably assess RA diagnosis as soon as the
first visits to the rheumatologist.
Conclusion
There is a substantial gap between CPG and rheumatologists  daily practice concerning the first DMARD to prescribe in early RA. It’
is explained mainly by diagnostic uncertainty. More attention should be paid in future guidelines to the diagnostic difficulties of early
RA.
MESH Keywords Adolescent ; Adult ; Aged ; Antirheumatic Agents ; therapeutic use ; Arthritis, Rheumatoid ; diagnosis ; drug therapy ; Early Diagnosis ; Female ; France 
; Humans ; Male ; Middle Aged ; Physician's Practice Patterns ; standards ; statistics & numerical data ; Practice Guidelines as Topic ; Prospective Studies ; Rheumatology ; 
methods ; standards ; Time Factors ; Uncertainty ; Young Adult
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INTRODUCTION
Promulgation of clinical practice guidelines (CPG) is intended to synthesise available medical information and improve quality of
care.  Barriers to their application, however, often limit their implementation in daily practice. ,  Actual application depends on[3 –9 ] [10 11 ]
a variety of indicators, including confidence in the guideline developer , , accessibility of the guidelines, their ease of use , and[12 13 ] [14 ]
applicability to specific patients, as well as the strategies used to promote implementation. , [15 16 ]
Rheumatoid arthritis (RA) is interesting to consider from this point of view because treatment for it has changed substantially in recent
years. Key aspects of these changes include early start of treatment, use of drugs that can prevent joint destruction (that is, proven to
prevent or delay structural damage) and disease flares, importance of regular monitoring of disease activity and structural changes to
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ensure tight control of the disease.  For this reason, several expert groups and professional societies have issued guidelines on this[17 –22 ]
topic in recent years. , , , [1 2 23 24 ]
Two different groups produced two sets of guidelines about prescription of first-line disease-modifying antirheumatic drugs
(DMARD) in early RA: the French Society of Rheumatologists  STPR working group  (French acronym for Therapeutic strategies in’ [1 ] “
RA ) and a EULAR expert group  (European League Against Rheumatism). The STPR guidelines present a decision tree for choosing” [2 ]
the first DMARD to be used in early RA (less than 6 months duration).  The EULAR guidelines put methotrexate as the anchor drug[1 ]
that should be used first in patients at risk of developing persistent disease.[2 ]
To compare these CPG with the usual care provided by rheumatologists, we used the data of a French nationwide cohort, ESPOIR
(acronym for Study and Follow-up of Undifferentiated Early Arthritis ), which included patients between 2002 and 2005.  It is“ ” [25 ]
important to note the chronology: the ESPOIR inclusion period overlapped with the production and diffusion of both CPG. The STPR
results were presented at the ACR annual scientific meeting in November 2004 and published in January 2006, while the EULAR results
were presented at the EULAR annual scientific meeting in June 2005 and published in January 2007. Our aim therefore was not to assess
adherence to guidelines. Instead we sought to explore the potential gap between daily rheumatologic practice and guidelines for the first
DMARD prescription in early RA, before their dissemination, for such gaps are likely to be barriers to implementation.
PATIENTS AND METHODS
Study design
Our primary objective was to assess the conformity between the first DMARD prescribed to patients in the ESPOIR cohort and the
DMARD recommended by each of the two sets of guidelines. At the same time we assessed the determinants of this conformity, the
influence of the patient s inclusion date, and the extent of the gap with the STPR guidelines. Our secondary objective was to explore the’
reasons for any discrepancies we observed between the rheumatologists  decisions and CPG. Accordingly, in cases where the treatment did’
not match the STPR guidelines, we sent a questionnaire (described in Appendices) to the patients  attending rheumatologists.’
Patients
The ESPOIR cohort
ESPOIR was a nationwide prospective cohort study of adults (18 to 70 years old) sponsored by the French Society of Rheumatology.[
,  Inclusion criteria were: inflammatory arthritis for at least 6 weeks but not longer than 6 months, involvement of more than two25 26 ]
joints, clinical diagnosis of RA as certain or probable or clinical diagnosis of undifferentiated arthritis potentially becoming RA, and no
DMARD or steroid treatment since the onset of symptoms. Patients with other definite inflammatory rheumatic diseases or with too much
uncertainty of developing RA were excluded.
Recruitment in 14 university hospital rheumatology departments was conducted through several media inviting patients and physicians
to participate in each regional area. Each centre acted as an observational centre and did not interfere with patient treatment, except in
charge of a patient. The patients were routinely treated and followed by private rheumatologists of the geographical area.
In all, 813 patients were recruited from November 2002 to April 2005 and have been longitudinally followed since then, seen every 6
months in the 14 hospital centres participating in the project. Baseline data is updated at the 6-month follow-up.
RA diagnosis
A selection of patients most at risk to be RA patients was conducted in ESPOIR database, to allow a study of conformity with
guidelines in case of the less diagnostic uncertainty of RA. Therefore fulfilment of ACR criteria  and the attending rheumatologist s[27 ] ’
diagnostic certainty at baseline (0 to 100 visual analogue scale  VAS) were used.–
‘Definite RA  was defined if patients met at least 4 (of 7) ACR criteria and diagnostic certainty was rated at 75 (threshold determined’ ≥
by ESPOIR steering committee). Probable RA  was defined as meeting at least 3 ACR criteria, even with a diagnostic certainty <75.‘ ’
Guidelines
STPR guidelines:[1 ]
The STPR decision tree determines the DMARD to prescribe according to 3 items: level of disease activity based on the Disease
Activity Score for 28 joints (DAS28) (low: 3.2; moderate: 3.2 5.1; high: 5.1), the presence of structural damage, and rheumatoid factor≤ – ≥
(RF) status. The decision tree leads to four possible therapeutic options of increasing severity. Each calls for the choice of one of two
DMARDs: A/hydroxychloroquine or sulfasalazine, B/sulfasalazine or methotrexate, C/methotrexate or leflunomide, D/methotrexate or
TNF-blocker agents. ( )Appendix 1 
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EULAR guidelines:[2 ]
These guidelines recommend methotrexate as a first treatment for early arthritis at risk to be persistent, since it acts on structural
damage, prevents flares and may thus be viewed as an anchor drug for additional DMARDs in case of inadequate response.
Conformity with guidelines
We then assessed conformity with the STPR and the EULAR guidelines. To evaluate STPR conformity we needed data about the 3
items of the STPR algorithm whereas to evaluate EULAR conformity we were able to compare therapeutic decision with the
recommended treatment everytime.
Possible determinants of conformity studied were: social and demographic patient characteristics (sex, age, ethnic origin, educational
level, comorbidities), disease characteristics (number of tender joints, number of swollen joints, symptoms duration, DAS28 score, HAQ
score), prognostic factors (presence of rheumatoid factor (RF) or Anti-CCP antibodies (CCP-Abs), presence of radiographic erosions,
erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels), category of diagnostic certainty (definite versus probable RA)
and finally the geographical area of inclusion.
In view of the length of the ESPOIR inclusion period, we also assessed the influence of the inclusion period, subdivided into four
quartiles (November 2002 through May 2003, June 2003 through December 2003, January 2004 through June 2004, and July 2004 through
April 2005).
When treatment was not the same as the STPR guidelines, the discrepancy could be either important or slight. We therefore pooled the
different treatment decisions in 3 broad categories: no DMARD prescription, prescription of DMARD that only prevents flares
(hydroxychloroquine, gold salts, tiopronin), and prescription of at least one DMARD that prevents flares and has been proven to inhibit
structural damage (methotrexate, leflunomide, sulfasalazine and TNF-blocker agents). We then assessed the observed and expected
(according to STPR guidelines) DMARD prescriptions according to these three categories.
Mail survey
In May 2007, a survey was mailed to the initial attending rheumatologists of all patients whose treatment differed from STPR
guidelines. The questionnaire was carefully phrased to not seem judgmental, especially since no aspect of either CPG was mandatory. All
therapeutic options were presented at the same level, without any labeling as good or bad, optimal or suboptimal. The questionnaire asked
about the reasons for the decision and then about awareness of the STPR and EULAR guidelines. Rheumatologists were also asked about
their perception of the guidelines  pertinence and the decision they would make for a similar patient visiting in 2007.’
Statistical analysis
Statistical analysis used SAS software, version 9-1 (SAS Institute Inc., Cary, NC, USA). Conformity was scored 1 if the treatment and
guidelines matched and 0 if not. Conformity was expressed as a percentage. Categorical variables were compared with Pearson s 2-test or’ χ
Fisher s exact test, as appropriate. The statistical significance level was set at 0.05 in two-tailed tests.’  α =
Univariate analyses determined the factors associated with conformity. Multivariate logistic regression with generalized estimating
equations (mixed model) was used to account for the clusters (14 hospital centres). Variables with a p-value less than 20  were kept in the%
final model. The likelihood of dependent variables is presented as odds ratios with their 95  confidence intervals. The responses to the%
mail survey are expressed as percentages.
Ethics Committee
The ESPOIR study was approved by the central ethics committee of Montpellier, and written informed consent was obtained from
each participant in the cohort. Both the scientific and steering committee of the ESPOIR cohort approved this study.
RESULTS
Of the 813 cohort members, 627 had definite or probable RA and were included in the further analysis. ( )Figure 1 
Baseline patient characteristics
summarises the main baseline characteristics of the 627 patients. They were predominantly female (76.6 ), and their meanTable 1 %
age was 48.7 years. Almost 30  had at least one comorbid disease at inclusion. They presented with active, very recent-onset disease:%
mean tender joint count was 9.4 /  7.1, mean swollen joint count 8.2 /  5.3, mean DAS28 5.4 /  1.2, and mean symptom duration+ − + − + −
(from onset of the first persistently swollen joint) less than 15 weeks.
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In all, 505 patients (80.5  of 627 patients) began DMARD treatment within a mean of 17.6 /  9.1 weeks (median 16.4) from the% + −
onset of the first persistently swollen joint. The DMARD prescribed most frequently was methotrexate  in 340 patients (54.2  of 627).— %
Combination therapies were noted in 41 patients (6.5 ). ( )% Table 2 
Conformity with guidelines
Conformity with the STPR guidelines could be determined for 581 patients (92.7 ) ( ) and ranged between centres from 35 to% Figure 1 
79 . Overall, 337 DMARD prescriptions (58.0 ) matched the STPR guidelines (66  in the group definite RA  and 47  in the group % % % “ ” % “
probable RA ).”
Conformity with the EULAR guidelines could be determined for all 627 patients and ranged between centres from 22 to 75.4 . In all,%
340 DMARD choices (54.2 ) matched the EULAR guidelines (61  in the group definite RA  and 45  in the group probable RA ).% % “ ” % “ ”
Analysis of determinants associated with conformity
STPR guidelines
Results of the univariate analysis are presented in . The final multivariate analysis adjusted for inclusion centre, found threeTable 3 
variables to be significantly associated with conformity: presence of RF or CCP-Abs and a definite  diagnosis of RA were associated with‘ ’
better conformity (odds ratios >1), while poorer conformity was found for women patients (odds ratios <1). ( )Table 4 
EULAR guidelines
The data from the univariate analysis are not shown. The multivariate analysis, adjusted for inclusion centre, found the following
significant determinants associated with better conformity: moderate and high DAS28 scores, radiographic bone erosions, and the presence
of RF or CCP-Abs (odds ratios >1). ( )Table 4 
Influence of inclusion period
We observed a trend towards better conformity with the STPR guidelines over time during the ESPOIR inclusion period. During the
last period (July 2004 through April 2005), conformity with STPR reached 67.4 , compared with 56.5  for the previous periods. This% %
difference was not, however, statistically significant ( 2 6.9, DF 3, p 0.07).χ = = =
Importance of the divergence in cases of non-conformity with the STPR guidelines Overall, 433 (69.1 ) received at least one%
DMARD proven to inhibit structural damage, 72 (11.5 ) a DMARD that did not, and 122 (19.5 ) did not receive any DMARD until the% %
6-month follow-up visit.
We then focused on the 244 patients treated differently than the STPR guidelines recommend ( ): 116 (47.5 ) had mild toTable 5 %
moderate disease (no structural damage and low or moderate DAS28 scores). In this group, 62 patients (25.4 ) had no DMARD%
prescribed, 31 (12.7 ) only a flare-preventing DMARD, and 23 (9.4 ) at least one flare-preventing DMARD also proven to inhibit% %
structural damage. Of the 128 (52.5 ) with severe disease (either structural damage or high DAS28 score), 21 (8.6 ) had no DMARD% %
prescribed, 39 (16.0 ) only a flare-preventing DMARD, and 68 (27.9 ), at least one DMARD that inhibited structural damage and% %
prevented flares.
Mail survey
The mail questionnaire was sent out in May 2007 and the analysis was performed in August 2007: 204 separate surveys were sent to
124 rheumatologists. We received 113 answers (55.4  of 204) from 73 rheumatologists (58.9  of 124). ( )% % Figure 1 
They responded that their treatment decision was based, in decreasing order, on: diagnostic uncertainty (36.1 ), presumed best%
benefit/risk ratio (25.0 ), hospital decision (13.9 ), usual practice (7.4 ), patient decision (5.6 ), don t remember  (4.6 ), inclusion in a% % % % “ ’ ” %
clinical trial (3.7 ), and patient comorbidities (3.7 ). The percentages reported by respondents who decided not to use any DMARD% %
differed slightly, with diagnostic uncertainty accounting for 47.4  of the reasons; the order thereafter did not differ. At the time of the%
survey, 56 rheumatologists (76.7 ) were aware of the STPR guidelines and 59 (80.8 ) of the EULAR guidelines.% %
In 66 cases (58.4  of 113), the rheumatologist reported they would choose a different treatment now, and 57 (50.4 ) would choose% %
the treatment recommended by STPR. The main reason for continued disagreement with STPR guidelines remained diagnostic uncertainty.
DISCUSSION
Our study demonstrates a rather substantial discrepancy between the recently published guidelines for the first-line DMARD to be
prescribed for patients with early RA, and daily French practice between 2002 and 2005.
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We have not found similar data in the literature with which we can compare our results. Although some studies that retrospectively
assessed the application of CPG for therapeutic decisions report conformity rates ranging from 40 to 60 , study designs and methods vary%
greatly. ,  For example, in the field of rheumatology, Denoeud et al. showed that the French general practitioners treating[8 28 –30 ]
osteoarthritis of the knee conform with the EULAR guidelines in 54  of the cases.  The conformity rates in our study, even before% [28 ]
implementation of the CPG, are rather encouraging and suggest rheumatologists will find them acceptable.
The conformity with guidelines improved during the study period with a rate of 67  for the STPR guidelines during the last period of%
ESPOIR inclusions. There were connections between the members of the STPR group and the ESPOIR steering committee as a few people
participated in both groups (AC, BC, BF, RMF, XLL, OM, AS). This could have led to better dissemination of STPR guidelines in the
ESPOIR inclusion centres, even if patients were followed by their usual rheumatologist. Moreover some discrepancies have been observed
in the different centres which might be due to local prescription habits or impact of local opinion leaders. Some of the ESPOIR centres are
also important recruitment centres for clinical trials which lead to DMARD prescriptions different from guidelines. However, treatment
decisions were made by usual practising rheumatologist and not directly by the people involved in the recruitment and follow-ups of the
ESPOIR patients.
Our study found quite similar rates of conformity for both sets of guidelines, which recommend methotrexate as the principal
treatment in early RA. Of the 505 (67 ) patients who received a DMARD in this study, 340 were prescribed methotrexate. These results%
are similar to those in other studies. Methotrexate is the leading DMARD prescribed for RA in Europe, the United States, and Australia; it
accounts for 46 to 83  of all DMARDs prescribed, according to country.% [31 –36 ]
We also wondered if the results of conformity with EULAR guidelines would be different by assuming that using leflunomide as a
first DMARD was equivalent to use methotrexate. The rate of conformity was then 59.2  instead of 54.2 .% %
A key point in the recent therapeutic advances in the management of RA is the need to start treatment early with a DMARD that
reduces joint damage (radiographic progression). , ,  Delaying its initiation in patients with early RA is thus very clearly[18 20 22 ]
suboptimal treatment. The STPR and EULAR guidelines differ in that STPR grades the prescription according to disease activity and
factors predictive of severity (structural damage, RF status). In particular, the STPR group does not recommend methotrexate for RA
patients who have a low DAS28 and no structural damage and are negative for RF, that is, for mild or perhaps doubtful RA. The
randomized controlled PROMPT study points in the same direction. It showed in a subgroup of patients with early arthritis who were
negative for RF and CCP-Abs and thus might not develop RA that methotrexate did not improve patient outcomes at 3 years.  The[37 ]
STPR guidelines rely on this concept and introduce treatment that is graded according to the potential benefit/risk ratio of methotrexate,
compared with other conventional DMARDs, such as hydroxychloroquine.
It was also interesting to determine whether the patients treated differently than the STPR guidelines recommend had received a
DMARD that stops joint damage. Although only 23 of the 116 patients with mild or moderate disease (20 ), had been treated with such a%
drug, negative consequences to this lack of treatment were least likely in this group.  On the other hand, 60 of the 128 patients with[37 ]
severe disease (47 ) had still not received a DMARD effective against structural involvement 6 months after inclusion in the study, and%
their treatment can be considered suboptimal, as several authors have shown. , , [20 38 39 ]
An important reason for non-conformity with guidelines and, by extension, for suboptimal care is diagnostic uncertainty, which is a
well-known difficulty in the management of early RA. Classification criteria and clinical standards for diagnosis are useful after 1 or 2
years of disease, but not necessarily at the first consultation. In practice, early arthritis is frequently undifferentiated.  An RA diagnosis[40 ]
is thus generally based upon the rheumatologist s opinion, perhaps after consideration of the ACR classification criteria , as here. These’ [27 ]
criteria do not, however, perform as well in early arthritis as they do in established RA.  Other criteria, such as those from the Leiden[41 ]
clinic , have been developed to address early RA diagnosis more specifically.[42 ]
Some limitations in our study must be noted. Although the cohort was observational and intended for the study of routine practice, it is
not certain that mere participation did not influence rheumatologists  treatment decisions and thereby introduce possible bias. Furthermore,’
compliance bias undoubtedly plays a role in physicians  answers to questions about their practices, because it is well known that the even’
experts  answers about their prescription habits are sometimes rather far from their real practice, as Headrick et al showed.’ [43 ]
To conclude, we found a gap between recent guidelines for treatment of early RA and daily practice by specialists during the period
the guidelines were under development. In some cases, especially when the RA diagnosis is uncertain or predictive factors of severity are
absent, these differences are unlikely to be harmful. In other cases, however, care appeared to be suboptimal. Future efforts will concern
the establishment of reliable criteria for diagnosis of early RA, necessary to improve the implementation of the treatment guidelines.
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APPENDICES
Appendix 1. Therapeutic options recommended by STPR for prescription of first DMARD in early RA, derived
from the STPR guidelines [1 ]
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Patients No structural damage With structural damage
DAS28 RF negative RF positive RF negative RF positive
Low: 0 3.2– A B C C
Moderate: 3.2 5.1– B B C C
High: >5.1 C C C D
DAS 28: Disease Activity Score on 28 joints; RF: rheumatoid factor Four Therapeutic options recommended by STPR for prescription of first DMARD in early RA:
A: Hydroxychloroquine or sulfasalazine
B: Sulfasalazine or methotrexate
C: Methotrexate or leflunomide
D: Methotrexate or TNF-blocker agents
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Appendix 2: Questionnaire mailed to patients  attending rheumatologists’
Patient N°
Dear colleague,
You participated in the ESPOIR cohort between 2002 and 2005, by including a patient on the ../../…
Your patient, Mr (Mrs) xxx/xx,  years old, presented with :…
-  tender joints,  swollen joints,… …
- Erythrocyte Sedimentation Rate was  mm at 1st hour, C-Reactive Protein was  mg/L, Rheumatoid Factor was positive/negative.… …
- DAS 28 was ,…
- Radiography showed some (did not show any) structural damage typical of rheumatoid arthritis (RA).
The therapeutic decision was to: start  (not start) a DMARD.…
I) Can you explain the reasons leading to this therapeutic decision, reviewing your file if necessary?
(Please circle the answer you prefer)
This was my usual practice
This option had the best benefit/risk ratio
This was the best option because of patient comorbidities
The RA diagnosis was uncertain
Therapeutic decision was due to hospital colleagues
The patient refused another proposal
The patient was included in a clinical trial
I don t remember’
II) Various guidelines have been published for choosing the first DMARD for patients presenting with early RA. Are you aware of the
following guidelines?
(Please fill in one circle per item)
STPR, in 2006 Le Lo t X. et al., ARD 2006;65;45 50.ë –
Yes
No
EULAR, in 2007 Combe B. et al., ARD2007;66;34 45.–
Yes
No
III) Considering these guidelines and their impact in your practice, how would you treat a similar case today?
(Please circle the answer you prefer)
Would not start a DMARD.
Introduction of:
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Hydroxychloroquine
Sulfasalazine
Gold salts
Methotrexate
Leflunomide
Combined therapy:
Hydroxychloroquine  sulfasalazine+
Methotrexate  hydroxychloroquine+
Methotrexate  sulfasalazine+
Methotrexate  leflunomide+
Methotrexate  gold salts+
Methotrexate  hydroxychloroquine  gold salts+ +
TNF-blocker agent alone or with another DMARD
Others:
IV) In a similar case, the STPR work group (Strat gies Th rapeutiques dans la Polyarthrite Rhumato de) would have recommended:é é ï
Either , either , as a single treatment.… …
Do you agree with this guideline in this patient s case?’
(Please circle the answer you prefer)
Yes
No
If you answered  No , please circle the reason why or describe why under other :« » “ ”
➢ This is not my usual practice
➢ This option does not have the best benefit/risk ratio
➢ This is not the best option because of patient comorbidities
➢ The diagnosis of RA is uncertain
➢ I think that a combination of DMARDs is needed, included one of the drugs recommended
➢ I think that a combination of DMARDs is needed, not including either of the two recommended drugs
➢ Other:
Footnotes:
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Figure 1
Study design
RA: Rheumatoid arthritis 1 581 patients had complete sets of data (DAS 28 score, the structural damage status and RF status) (92.7 )2 %
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Table 1
Patient baseline characteristics
ESPOIR cohort patients ‘Definite  and Probable  RA n 627’ ‘ ’ =
Social and demographic characteristics
 Women, n ( )% 480 (76.6)
 Age (years),  mean / + − SD (median) 48.7 /  12.4 (51.1)+ −
 Caucasian, n ( )% 582 (92.8)
 Post-secondary level of education, n ( )% 96 (15.3)
History/Comorbidities
 Personal or familial history of psoriasis, n ( )% 103 (16.4)
 At least one comorbid factor ,  * n ( )% 178 (28.7)
 BMI (kg/m ),   ** 2 mean / + − SD (median) 25.2 /  4.6 (24.5)+ −
Disease characteristics
 Tender joints ,   *** mean / + − SD (median) 9.4 /  7.1 (8.0)+ −
 Swollen joints ,   *** mean / + − SD (median) 8.2 /  5.3 (7.0)+ −
 Symptom duration (weeks),  mean / + − SD (median) 14.7 /  7.5 (13.4)+ −
 DAS28 value,   ** mean / + − SD (median) 5.4 /  1.2 (5.3)+ −
 HAQ ,   ** mean / + − SD (median) 1.0 /  0.7 (1.0)+ −
Prognostic factors
 Positive for RF ,  ** n ( )% 343 (54.7)
 Positive for CCP-Abs ,  ** n ( )% 278 (44.8)
 Presence of bone erosion on x-ray, n ( )% 146 (26.0)
 ESR (mm at 1 hour),   ** mean / + − SD (median) 30.4 /  24.4 (24.0)+ −
 CRP (mg/L),   ** mean / + − SD (median) 23.4 /  34.3 (10.0)+ −
RA diagnosis
 Fulfilled 4 ACR criteria,  ** n ( )% 539 (86.0)
 RA diagnostic certainty on 0 100 VAS,  – mean / + − SD (median) 78 /  18 (80)+ −
 Patients with,
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  Definite RA , ‘ ’ n ( )% 359 (57.3)
  Probable RA , ‘ ’ n ( )% 268 (42.7)
 * Presence of at least 1 comorbid factor among following items: ischemic heart disease, diabetes mellitus, hypertension, renal disease (clearance <60 ml/min or proteinuria or hematuria), current cancer,
or chronic viral infection (HIV, HBV, HCV)
 ** BMI: Body Mass Index; DAS28: Disease Activity Score on 28 joints; HAQ: Health Assessment Questionnaire; RF: Rheumatoid factor; CCP-Abs: Anti-CCP antibodies; ESR: Erythrocyte
sedimentation rate; CRP: C-reactive protein; ACR: American College of Rheumatology
 *** Number of tender and swollen joints on a 28-joint count
Table 2
Details of therapeutic decisions
Type of DMARD prescribed ‘Definite  and Probable  RA n 627’ ‘ ’ =
No DMARD prescribed 122/627 (19.5 )%
One DMARD prescribed 464/627 (74.0 )%
 Methotrexate 300/464 (64.7 )%
 Sulfasalazine 59/464 (12.7 )%
 Hydroxychloroquine 58/464 (12.5 )%
 Leflunomide 31/464 (6.7 )%
 others 14/464 (3.0 )%
 TNF-blocker agents (Etanercept, Adalimumab) 2/464 (0.4 )%
Two DMARDs prescribed 32/627 (5.1 )%
 Methotrexate  hydroxychloroquine+ 18/32 (56 )%
 Methotrexate  TNF-blocker agents (Etanercept, Adalimumab)+ 8/32 (25 )%
 Methotrexate  + others 3/32 (10 )%
 Methotrexate  sulfasalazine+ 2/32 (6 )%
 Hydroxychloroquine  sulfasalazine+ 1/32 (3 )%
Three DMARDs prescribed 9/627 (1.4 )%
 Methotrexate  hydroxychloroquine  gold salts+ + 9/9 (100 )%
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Table 3
Conformity with STPR guidelines and univariate analysis of determinants
Determinants N 581= % of Conformity p
Sex
 Male 141 65.3 0.04
 Female 440 55.7
Post-secondary level of education
 No 493 60.0 0.02
 Yes 88 46.6
Personal or familial history of psoriasis
 No 484 60.3 0.01
 Yes 97 46.4
Number of swollen joints (28 joint count)
 0 3– 105 49.5 0.04
 4 8– 238 55.9
 9 28– 238 63.9
DAS28 value*
 0 3.2– 29 37.9 0.03
 3.2 5.1– 232 56.0
 >5.1 318 61.6
Elevated level of ESR*
 No 305 53.8 0.02
 Yes 274 63.1
Positive for RF and/or CCP-Abs * *
 No 237 45.6 <0.001
 Yes 344 66.6
‘Definite  RA’
 No 249 47.0 <0.001
 Yes 332 66.3
Fulfilled 4 ACR criteria for diagnosis of RA*
 No 80 42.5 0.003
 Yes 501 60.5
Observational centre (14 centres) 19 to 62 Range: 35.0 to 79.0 -
 * DAS28: Disease Activity Score on 28 joints; ESR: Erythrocyte sedimentation rate; RF: Rheumatoid factor; CCP-Abs: Anti-CCP antibodies; ACR: American College of Rheumatology
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Table 4
Multivariate Analysis of determinants of conformity with guidelines
Variables Odds Ratio 95  Confidence Interval% p
Conformity with STPR guidelines
 Women 0.70 0.50  0.98– 0.04
 Positive for RF and/or CCP-Abs * * 1.96 1.34  2.87– <0.001
  Definite  RA‘ ’ 1.77 1.29  2.44– <0.001
Conformity with EULAR guidelines
 DAS28 value*
  3.2 5.1 0 3.2– vs – 3.03 1.28  7.18– 0.01
  >5.1 0 3.2vs – 4.18 1.57  11.1– 0.004
 Positive for RF and/or CCP-Abs * * 2.28 1.71  3.02– <0.001
 Bone erosion on x-ray 1.45 1.01  2.08– <0.05
 * DAS28: Disease Activity Score on 28 joints; RF: Rheumatoid factor; CCP-Abs: Anti-CCP antibodies
Table 5
Comparison of the observed prescribed DMARDs classified in 3 categories with STPR-recommended therapeutic options in the 244 patients treated differently from STPR guidelines.
STPR-recommended Therapeutic Options
A B C D Total
N 35= N 81= N 120= N 8= N 244=
Observed prescribed DMARD
No DMARD prescribed 32 30 20 1 83 (34.0 )%
Only flare-preventing DMARD 0 31 38 1 70 (28.7)
At least one DMARD with proven structural effect 3 20 62 6 91 (37.3 )%
Four Therapeutic Options recommended by STPR for prescription of first DMARD in early RA ( ):appendix 1 
A: Hydroxychloroquine or sulfasalazine
B: Sulfasalazine or methotrexate
C: Methotrexate or leflunomide
D: Methotrexate or TNF-blocker agents
